MBX Biosciences, Inc. (MBX)
NASDAQ:MBX
MBX Stock Chart & Stats
$28.14
-$0.30(-2.05%)
At close: 4:00 PM EST
$28.14
-$0.30(-2.05%)
Day’s Range― - ―
52-Week Range$4.81 - $44.89
Previous CloseN/A
Volume52.29K
Average Volume (3M)552.46K
Market Cap
$1.34B
Enterprise Value$875.66M
Total Cash (Recent Filing)$373.70M
Total Debt (Recent Filing)$596.00K
Price to Earnings (P/E)―
Beta2.05
Next Earnings
May 18, 2026EPS Estimate
-0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding47,510,242
10 Day Avg. Volume551,085
30 Day Avg. Volume552,455
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)3.12
Price to Sales (P/S)0.00
P/FCF Ratio-14.06
Enterprise Value/Market Cap0.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.47K
Enterprise Value/Ebitda-9.17
Forecast
1Y Price Target
$64.20Price Target Upside128.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.95
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial DesignAnalyst highlights FDA alignment on the Phase III design and a study size chosen to detect normalization of urinary calcium, which could support an additional label claim and clinical differentiation.
Obesity Program Technology ValidationAnalyst notes obesity program data could validate MBX's prodrug technology by demonstrating infusion‑like drug exposure and improved tolerability, increasing the program's appeal to partners.
Therapeutic ComparabilityAnalyst expects the Phase III to confirm earlier results that canvu provides parathyroid hormone replacement comparable to an approved treatment, strengthening commercial differentiation versus existing therapies.
Bears Say
Clinical Trial Outcome RiskAnalyst warns there is a risk the Phase III may not reproduce earlier positive results, which would weaken the investment thesis and reduce partner interest.
MBX Biosciences, Inc. News
MBX FAQ
What was MBX Biosciences, Inc.’s price range in the past 12 months?
MBX Biosciences, Inc. lowest stock price was $4.81 and its highest was $44.89 in the past 12 months.
What is MBX Biosciences, Inc.’s market cap?
MBX Biosciences, Inc.’s market cap is $1.34B.
When is MBX Biosciences, Inc.’s upcoming earnings report date?
MBX Biosciences, Inc.’s upcoming earnings report date is May 18, 2026 which is in 52 days.
How were MBX Biosciences, Inc.’s earnings last quarter?
MBX Biosciences, Inc. released its earnings results on Mar 23, 2026. The company reported -$0.49 earnings per share for the quarter, beating the consensus estimate of -$0.63 by $0.14.
Is MBX Biosciences, Inc. overvalued?
According to Wall Street analysts MBX Biosciences, Inc.’s price is currently Undervalued.
Does MBX Biosciences, Inc. pay dividends?
MBX Biosciences, Inc. does not currently pay dividends.
What is MBX Biosciences, Inc.’s EPS estimate?
MBX Biosciences, Inc.’s EPS estimate is -0.57.
How many shares outstanding does MBX Biosciences, Inc. have?
MBX Biosciences, Inc. has 47,510,242 shares outstanding.
What happened to MBX Biosciences, Inc.’s price movement after its last earnings report?
MBX Biosciences, Inc. reported an EPS of -$0.49 in its last earnings report, beating expectations of -$0.63. Following the earnings report the stock price went down -1.883%.
Which hedge fund is a major shareholder of MBX Biosciences, Inc.?
Currently, no hedge funds are holding shares in MBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MBX Biosciences, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$64.20 (128.14% Upside)
$64.20 (128.14% Upside)
Blogger Sentiment
Bullish
MBX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 624.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $525.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
271.75%
12-Months-Change
Fundamentals
Return on Equity
-28.72%
Trailing 12-Months
Asset Growth
43.42%
Trailing 12-Months
Company Description
MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
MBX Stock 12 Month Forecast
Average Price Target
$64.20
▲(128.14% Upside)
Technical Analysis
KalVista Pharmaceuticals
―
Gossamer Bio
―
Nurix Therapeutics
―
Terns Pharmaceuticals
―
Tyra Bioscience
―
Ownership Overview
Currently, No data available
---